Specialized Hospital For Active Cardiology Treatment Medica Kor EAD

The Specialized Hospital For Active Cardiology Treatment Medica Kor EAD conducts research in cardiovascular disease. The trials target hypercholesterolemia and evaluate a novel RNA‑based therapy to improve LDL‑C control.

• Assess proportion of participants achieving individualized LDL‑C targets
• Evaluate safety when added to standard lipid‑lowering regimens
• Measure impact on patient‑reported quality of life

Two investigators oversee the program, highlighting the site’s focus on preventive cardiology.

The Department of Cardiology at the hospital addresses structural heart disease. This study enrolls patients with hypertrophic cardiomyopathy to test a new SGLT‑1/2 inhibitor for symptom relief.

• Track changes in exercise capacity and functional limitation
• Compare symptom scores between active treatment and placebo
• Monitor safety and tolerability in a high‑risk population

The project involves two senior cardiologists and reflects ongoing efforts to enhance quality of life for HCM patients.

Researchers at the site focus on acute coronary events. The trial investigates ziltivekimab as an early intervention for patients experiencing myocardial infarction to lower inflammatory markers and event risk.

• Initiate therapy shortly after STEMI or NSTEMI
• Evaluate reduction in major adverse cardiovascular events
• Observe safety when combined with standard post‑MI care

With two investigators leading, the study underscores the hospital’s commitment to innovative post‑acute care strategies.

The clinic’s cardiovascular program also targets persistent hypertension. This research examines zilebesiran in individuals with high cardiovascular risk to determine its effect on blood pressure and event outcomes.

• Determine impact on cardiovascular death, non‑fatal MI, and stroke
• Assess reduction in systolic and diastolic blood pressure
• Compare efficacy against placebo in a high‑risk cohort

The study is driven by two principal investigators, reflecting the site’s dedication to improving hypertension management.